(Q45064639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

coronary artery disease

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Anthony H Barnett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Helen L Millar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Jean-Yves Loze

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Gilbert J L'Italien

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Marc van Baardewijk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

1 reference

9 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

European Archives of Psychiatry and Clinical Neuroscience

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

239-247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19267255%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00406-008-0863-2

22 January 2020

exact match

0 references

cites work

Chart-recorded psychiatric diagnoses in women giving birth in California in 1992.

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0863-2

The global costs of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0863-2

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0863-2

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-008-0863-2

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

21 January 2018

1 reference

12 December 2020

Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

1 reference

12 December 2020

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

1 reference

12 December 2020

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

1 reference

12 December 2020

Cost of cardiovascular diseases in the United Kingdom

1 reference

12 December 2020

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

1 reference

12 December 2020

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia

1 reference

12 December 2020

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design

1 reference

12 December 2020

Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

1 reference

12 December 2020

Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes

1 reference

12 December 2020

Atypical antipsychotics and glucose dysregulation: a systematic review

1 reference

12 December 2020

Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.

1 reference

12 December 2020

Do people with type 2 diabetes and their carers lose income? (T2ARDIS-4)

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

Dopamine partial agonists: a new class of antipsychotic

1 reference

12 December 2020

Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients

1 reference

12 December 2020

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

1 reference

12 December 2020

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

1 reference

12 December 2020

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

12 December 2020

Excess mortality of schizophrenia. A meta-analysis

1 reference

12 December 2020

Number needed to treat (NNT): implication in rheumatology clinical practice

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Causes of the excess mortality of schizophrenia

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland

1 reference

12 December 2020

Costs of coronary heart disease and stroke: the case of Sweden.

1 reference

12 December 2020

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

12 December 2020

Direct medical costs for patients with type 2 diabetes in Sweden.

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients

1 reference

12 December 2020

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

12 December 2020

Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

12 December 2020

Mortality in a cohort of patients with schizophrenia: a record linkage study

1 reference

12 December 2020

Schizophrenia and increased risks of cardiovascular disease

1 reference

12 December 2020